Evidence map›Paper›PMID 33724917›Full record

ArticleDeutsches Arzteblatt international2021

The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors.

Knut Mai, Martin Fassnacht, Dagmar Führer-Sakel, Jürgen B Honegger, Matthias M Weber, Matthias Kroiss

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Deutsches Arzteblatt international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05601141 (Pituitary Diseases in Modena Population), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05601141 recruitingnot on this mapstarted 2022, after this paper: background citation

Pituitary Diseases in Modena Population: Clinical and Epidemiological Data Register of Pituitary Patients Attending the Unit of Endocrinology of Azienda Ospedaliero-Universitaria of Modena (DataPit)

Typeobservational_patient_registrySponsorAzienda Ospedaliero-Universitaria di ModenaRan2022 to 2031Enrolled1,500ConditionsPituitary
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. [Endocrine side effects of tumor treatment].Innere Medizin (Heidelberg, Germany) · 2024
    Article
  2. Article
  3. Bioactives ofMolecules (Basel, Switzerland) · 2022
    Review
  4. Associations of Endocrine Functions and Hormone Axes.Deutsches Arzteblatt international · 2021
    Article
  5. In Reply.Deutsches Arzteblatt international · 2021
    Article
  6. The Focus Should Be On "Vitally Important" Hormone Axes.Deutsches Arzteblatt international · 2021
    Article
  7. Diabetes Insipidus Should Be Included.Deutsches Arzteblatt international · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Knut Mai
Martin Fassnacht
Dagmar Führer-SakelORCID 0000-0003-0357-4192
Jürgen B Honegger
Matthias M Weber
Matthias Kroiss

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immunologically mediated side effects of immune checkpoint inhibitors (CPI) often involve the endocrine system as well, and they can even be fatal, as in the case of unrecognized hypophysitis. Distinguishing such side effects from tumor-related changes is often difficult, because their clinical features can be nonspecific.

methodsThis review is based on publications retrieved by a selective search in PubMed, with special attention to international recommendations.

resultsDepending on their target molecules, the CPI now in use differ from one another in the incidence of side effects such as autoimmune thyroid disease (4-16%), hypophysitis (0.1- 18%), adrenalitis (0.7-8%), and autoimmune diabetes mellitus (0.5-2%). The typical clinical warning signs and laboratory constellations of hypophysitis include exhaustion, hyponatremia, and headache. Hypo- and hyperthyroidism and primary adrenocortical insufficiency likewise have nonspecific manifestations. Autoimmune diabetes mellitus often takes a fulminant course. Patients being treated with CPI should be monitored at close intervals, at least as frequently as the administration of the drug, so that endocrine side effects can be recognized in time. In case of doubt, glucocorticoid supplementation should be given whenever hypocortisolism is suspected, even before endocrine evaluation is completed and the results are available. Interrupting or discontinuing CPI treatment is rarely indicated.

conclusionWith the increasing number of patients being treated with CPI, more and more physicians from a wide variety of specialties, not necessarily working in specialized centers, now have to consider immunologically mediated endocrine side effects in the differential diagnosis, and treat them properly when they arise. These things should be done in collaboration with endocrinologists. The ongoing study of such side effects of the CPI now in use, and of those that will be introduced in the future, is important and will lead to improved understanding.

Identifiers

PMID33724917
PMCPMC8378258
OpenAlexW3138007006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.